医学
伊立替康
内科学
紫杉醇
化疗
危险系数
肿瘤科
不利影响
胃肠病学
中性粒细胞减少症
随机对照试验
外科
癌症
临床终点
置信区间
结直肠癌
作者
Shuichi Hironaka,Shinya Ueda,Hirofumi Yasui,Tomohiro Nishina,Masahiro Tsuda,Takehiko Tsumura,Naotoshi Sugimoto,Hideki Shimodaira,Shinya Tokunaga,Toshikazu Moriwaki,Taito Esaki,Michitaka Nagase,Kazumasa Fujitani,Kensei Yamaguchi,Takashi Ura,Yasuo Hamamoto,Satoshi Morita,Isamu Okamoto,Narikazu Boku,Ichinosuke Hyodo
标识
DOI：10.1200/jco.2012.48.5805
摘要
No statistically significant difference was observed between paclitaxel and irinotecan for OS. Both are reasonable second-line treatment options for advanced gastric cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Criminology34
大力的灵雁
鸟兽兽
GingerF
三四郎
eric888
YifanWang
无极微光
OsamaKareem
张欢馨
yorha3h
脆蜜金桔
Joyce
hsa_ID
arniu2008
Shawndy
loii
Mic
yue
干净的琦
皖公网安备34019202002308
